Pneumagen Targeting The Human Glycome To Block Viral Entry
COVID-19 Among Potential Uses
Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.
You may also be interested in...
The UK Government’s Therapeutics Taskforce has identified a number of drug candidates that could be used to treat COVID-19 and the first candidate is ready to enter clinical trials.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.